Ventricular natriuretic peptide

Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the European Society of Cardiology Heart Failure 2021

Retrieved on: 
Wednesday, June 30, 2021
Anatomy, Branches of biology, Organs anatomy), Heart diseases, Biomarkers, Cytokinetics, Organ failure, Ventricular natriuretic peptide, N-terminal prohormone of brain natriuretic peptide, Heart failure, Heart

Omecamtiv mecarbil may offer a new treatment option for these more severe heart failure patients who are also in greatest need.

Key Points: 
  • Omecamtiv mecarbil may offer a new treatment option for these more severe heart failure patients who are also in greatest need.
  • NT-proBNP is a biomarker of ventricular wall stress in which higher levels reflect more severe heart failure.
  • These results from GALACTIC-HF demonstrate a potentially clinically important treatment effect of omecamtiv mecarbil in patients with severe heart failure.
  • For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Cytokinetics Announces Results From GALACTIC-HF Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in the New England Journal of Medicine

Retrieved on: 
Friday, November 13, 2020
Cytokinetics, Biomarkers, N-terminal prohormone of brain natriuretic peptide, Ventricular natriuretic peptide, Amgen, Companies, Teerlink, Branches of biology, Medicine

Omecamtiv mecarbil also significantly decreased NT-proBNP concentrations by 10% (95% CI 6-14%) at Week 24 compared to placebo.

Key Points: 
  • Omecamtiv mecarbil also significantly decreased NT-proBNP concentrations by 10% (95% CI 6-14%) at Week 24 compared to placebo.
  • Heart failure remains a growing clinical and economic burden as our global population continues to age, said John Teerlink, M.D.
  • We look forward to continuing to discuss next steps in this program with Amgen to inform a potential path forward.
  • Amgen holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to Cytokinetics specified development and commercialization rights.

MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020

Retrieved on: 
Friday, November 13, 2020
Medical specialties, Clinical medicine, Cardiomyopathy, Medicine, Hypertrophic cardiomyopathy, Sports medicine, Cardiology, Biomarkers, Ventricular natriuretic peptide, N-terminal prohormone of brain natriuretic peptide

Non-Clinical Data Show Mavacamten Surrogate Preserved Cardiac Function in Disease Model, Slowing Progression

Key Points: 
  • Non-Clinical Data Show Mavacamten Surrogate Preserved Cardiac Function in Disease Model, Slowing Progression
    BRISBANE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today presented clinical and non-clinical data related to mavacamten, MyoKardias investigative therapeutic in late-stage development for the potential treatment of hypertrophic cardiomyopathy (HCM), at the American Heart Associations Scientific Sessions 2020.
  • We are optimistic that these changes may ultimately point to the benefits of mavacamten treatment in the progression of HCM.
  • Treatment with mavacamten led to statistically significant reductions in left ventricular mass (LVMI), indicating that mavacamten is having an effect on cardiac structure.
  • CNN predictions of clinical measures from activity data found strong correlations for pVO2, NT-proBNP, KCCQ score, and E over e prime.

MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Retrieved on: 
Saturday, August 29, 2020
Medical specialties, RTT, Clinical medicine, Circulatory system, Hypertrophic cardiomyopathy, Sports medicine, Ventricular natriuretic peptide, HCM, N-terminal prohormone of brain natriuretic peptide, Cardiomyopathy, Septal myectomy, Disopyramide

The randomized, controlled, pivotal EXPLORER-HCM Phase 3 clinical trial enrolled 251 symptomatic, obstructive patients with HCM, most of whom were on standard background HCM therapy.

Key Points: 
  • The randomized, controlled, pivotal EXPLORER-HCM Phase 3 clinical trial enrolled 251 symptomatic, obstructive patients with HCM, most of whom were on standard background HCM therapy.
  • (1,2) The decrease in NT-proBNP was observed at the earliest timepoint measured (Week 4) and was sustained throughout the 30-week treatment period.
  • The EXPLORER-HCM Phase 3 trial enrolled a total of 251 patients with symptomatic (NYHA Class II or III), obstructive hypertrophic cardiomyopathy.
  • Mavacamten is initially being developed for the treatment of hypertrophic cardiomyopathy (HCM) and has received breakthrough therapy and orphan drug designations for symptomatic, obstructive HCM.

Cardiac Marker Analyzer Market Analysis 2011-2019 & 2020-2026 with the Impact of COVID-19

Retrieved on: 
Tuesday, July 21, 2020
Cardiology, Branches of biology, Clinical medicine, Medicine, Biomarkers, Chemical pathology, Cardiac marker, Myoglobin, CPK-MB test, Troponin, Ventricular natriuretic peptide, N-terminal prohormone of brain natriuretic peptide

DUBLIN, July 21, 2020 /PRNewswire/ -- The "Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 21, 2020 /PRNewswire/ -- The "Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals" report has been added to ResearchAndMarkets.com's offering.
  • The global Cardiac Marker Analyzer market is predicted to reach US$ 4.5 Billion by 2026.
  • Cobas H232 POC system permits rapid and easy determination of cardiac blood markers such as Troponin T, NT-proBNP, D-dimer, CK-MB and myoglobin.
  • Cardiac Marker Analyzer - Mergers, Acquisitions, Distribution, Partnership and Licensing Agreements
    The Cardiac Marker Analyzer Covered in the report are as follows: